EasySep™人APC正选试剂盒II

免疫磁珠细胞正选试剂盒

产品号 #(选择产品)

产品号 #17661_C

免疫磁珠细胞正选试剂盒

产品优势

  • 快速、简单
  • 无需分离柱

产品组分包括

  • EasySep™人APC正选试剂盒II(产品号 #17661)
    • EasySep™ APC分选抗体混合物,1 mL
    • 抗人CD32 FcR阻断剂,1 mL
    • EasySep™ Dextran RapidSpheres™磁珠,1 mL
    • RoboSep™ 管,用于一抗偶联抗体(手动使用时无需此项),1 vial
  • RoboSep™ 人APC正选试剂盒II(产品号 #17661RF)
    • EasySep™ APC分选抗体混合物,1 mL
    • 抗人CD32 FcR阻断剂,1 mL
    • EasySep™ Dextran RapidSpheres™磁珠,1 mL
    • RoboSep™ 管,用于一抗偶联抗体(手动使用时无需此项),1 vial
    • RoboSep™ 缓冲液(产品号 #20104)
    • RoboSep™过滤吸头(产品号#20125)
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

总览

EasySep™人APC正选试剂盒II可通过正选方式将APC(别藻蓝蛋白)偶联抗体结合的细胞分离出来。目的细胞被识别APC和葡聚糖包被的磁珠的抗体复合物标记。标记细胞通过EasySep™磁极被分选,无需使用分离柱。目的细胞被保留在试管中,而非目的细胞被倾倒出。

本产品替代EasySep™人APC正选试剂盒(产品号#18451)。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
 
亚型
细胞分选试剂盒
 
细胞类型
B 细胞,树突状细胞(DCs),粒细胞及其亚群,造血干/祖细胞,巨噬细胞,骨髓基质细胞,间充质干/祖细胞,单核细胞,单个核细胞,髓系细胞,NK 细胞,其它细胞系,血浆,T 细胞
 
种属

 
样本来源
Buffy Coat,Cord Blood,Leukapheresis,其它细胞系,PBMC
 
筛选方法
Positive
 
应用
细胞分选
 
品牌
EasySep,RoboSep
 
研究领域
免疫
 

Data Figures

Starting with human PBMCs, the purities of the start and final isolated fractions in the above example are 23.3% and 99.0%, respectively, using an APC-conjugated anti-human CD19 antibody and EasySep™ Human APC Positive Selection Kit II.

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17661
Lot #
All
Language
English
Catalog #
17661RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17661
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17661
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17661
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17661RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17661RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
17661RF
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Catalog #
17661RF
Lot #
All
Language
English

Resources and Publications

Educational Materials (7)

Publications (1)

Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors F. Stehle et al. The Journal of Biological Chemistry 2013

Abstract

The multikinase inhibitors sunitinib, sorafenib, and axitinib have an impact not only on tumor growth and angiogenesis, but also on the activity and function of immune effector cells. In this study, a comparative analysis of the growth inhibitory properties and apoptosis induction potentials of tyrosine kinase inhibitors on T cells was performed. Tyrosine kinase inhibitor treatment resulted in a dramatic decrease in T cell proliferation along with distinct impacts on the cell cycle progression. This was at least partially associated with an enhanced induction of apoptosis although triggered by distinct apoptotic mechanisms. In contrast to sunitinib and sorafenib, axitinib did not affect the mitochondrial membrane potential but resulted in an induction or stabilization of the induced myeloid leukemia cell differentiation protein (Mcl-1), leading to an irreversible arrest in the G2/M cell cycle phase and delayed apoptosis. Furthermore, the sorafenib-mediated suppression of immune effector cells, in particular the reduction of the CD8(+) T cell subset along with the down-regulation of key immune cell markers such as chemokine CC motif receptor 7 (CCR7), CD26, CD69, CD25, and CXCR3, was not observed in axitinib-treated immune effector cells. Therefore, axitinib rather than sorafenib seems to be suitable for implementation in complex treatment regimens of cancer patients including immunotherapy.

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • RoboSep™-S (Catalog #21000)
Sample Source Buffy Coat, Cord Blood, Leukapheresis, Other, PBMC
Selection Method Positive
Legal Statement: Users of this kit should ensure that they are entitled to use the antibody of interest. STEMCELL Technologies Inc. is not responsible for patent infringements or violations that may occur when using this product. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。